Overview of the CINTS-R Trial
Background
Neoadjuvant chemoradiotherapy (nCRT) is the standard treatment for locally advanced rectal cancer (LARC). New methods like total neoadjuvant therapy (TNT) and immunotherapy are promising. We need better ways to select patients for these treatments. Our previous research shows that circulating tumour DNA (ctDNA) can help predict treatment outcomes and guide therapy choices.
Trial Design
The CINTS-R trial is a large study to compare ctDNA-guided treatment with standard therapy for LARC patients. We will include 470 patients with specific cancer stages from seven centers in China. Patients will be randomly assigned to either the experimental group or the control group.
- Experimental Group: Will receive tailored neoadjuvant treatments based on ctDNA analysis.
- Control Group: Will receive standard modified nCRT.
The main goal is to measure the treatment failure rate after two years. We will also look at recurrence times, overall survival, disease-free survival, and quality of life.
Ethics and Sharing Results
This study has received ethical approval and will securely store all data. We will share our findings through academic publications and conferences.
Trial Registration
The trial is registered on ClinicalTrials.gov with ID NCT05601505.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI platform, DocSym, helps integrate clinical guidelines and research for better patient care.
Streamlining Healthcare
Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, making patient management easier.
Improving Outcomes
By using AI, clinics can enhance workflows, improve patient outcomes, and reduce paperwork. Learn more at aidevmd.com.
